首页> 外文期刊>ACS Chemical Biology >Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine A as a new CXCR4 ligand exhibiting antagonist activity
【24h】

Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine A as a new CXCR4 ligand exhibiting antagonist activity

机译:极简主义的基于混合配体/受体的CXCR4药效基团模型应用于海洋天然产物的小库,导致鉴定出phidianidine A为具有拮抗活性的新CXCR4配体

获取原文
获取原文并翻译 | 示例
       

摘要

Here, we present a minimal hybrid ligand/receptor-based pharmacophore model (PM) for CXCR4, a chemokine receptor deeply involved in several pathologies, such as HIV infection, rheumatoid arthritis, cancer development/progression, and metastasization. This model, considerably simpler than those thus far proposed for this receptor, has been used to search for new CXCR4 inhibitors in a small marine natural product library available at ICB-CNR Institute (Pozzuoli, NA, Italy), since natural products, with their naturally selected chemical and functional diversity, represent a rich source of bioactive scaffolds; computational approaches allow searching for new scaffolds with a minimal waste of possibly precious natural product samples; and our "stripped-down" model substantially increases the probabilities of identifying potential hits even in small-sized libraries. This search, also validated by a systematic virtual screening of the same library, has led to the identification of a new CXCR4 ligand, phidianidine A (PHIA). Docking studies supported PHIA activity and suggested its possible binding modes to CXCR4. Using the CXCR4-expressing/ CXCR7-negative GH4C1 cell line we show that PHIA inhibits CXCL12-induced DNA synthesis, cell migration, and ERK1/2 activation. The specificity of these effects was confirmed by the lack of PHIA activity in GH4C1 cells, in which siRNA highly reduces CXCR4 expression and the lack of cytoxicity of PHIA was also verified. Thus, PHIA represents a promising lead for a new family of CXCR4 modulators with wide margins of improvement in potency and specificity offered by the small and very simple underlying PM.
机译:在这里,我们为CXCR4提供了一个最小的基于混合配体/受体的药效团模型(PM),CXCR4是一种趋化因子受体,与多种病理学密切相关,例如HIV感染,类风湿性关节炎,癌症发展/进展和转移。这种模型比迄今为止为该受体提出的模型要简单得多,已被用于在ICB-CNR研究所(意大利那不勒斯的波佐利)提供的小型海洋天然产物库中寻找新的CXCR4抑制剂,因为天然产物及其自然选择的化学和功能多样性代表了丰富的生物活性支架;计算方法允许以最少的可能有价值的天然产物样品浪费寻找新的支架;而且我们的“精简”模型大大提高了即使在小型图书馆中也可以识别潜在匹配的可能性。该搜索也已通过对同一文库的系统虚拟筛选进行了验证,从而导致了新的CXCR4配体phidianidine A(PHIA)的鉴定。对接研究支持PHIA活性,并建议其可能与CXCR4结合的模式。使用表达CXCR4的/ CXCR7阴性的GH4C1细胞系,我们显示PHIA抑制CXCL12诱导的DNA合成,细胞迁移和ERK1 / 2活化。 GH4C1细胞缺乏PHIA活性证实了这些作用的特异性,其中siRNA大大降低了CXCR4的表达,也证实了PHIA缺乏细胞毒性。因此,PHIA代表了一个新的CXCR4调节剂家族的有前途的领导者,其潜在的优势是小而非常简单的潜在PM所提供的效力和特异性的改善。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号